IRIS
SANTORO, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.037
EU - Europa 2.968
AS - Asia 1.917
SA - Sud America 127
AF - Africa 39
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 1
Totale 30.101
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.977
SG - Singapore 973
IT - Italia 493
DE - Germania 479
IE - Irlanda 348
SE - Svezia 337
CN - Cina 324
UA - Ucraina 300
HK - Hong Kong 257
RU - Federazione Russa 235
KR - Corea 233
PL - Polonia 214
FR - Francia 177
GB - Regno Unito 140
BR - Brasile 105
FI - Finlandia 101
CA - Canada 52
ID - Indonesia 41
NL - Olanda 41
AT - Austria 31
VN - Vietnam 23
BE - Belgio 20
CZ - Repubblica Ceca 18
CM - Camerun 15
JP - Giappone 11
ES - Italia 10
EU - Europa 10
ZA - Sudafrica 10
PH - Filippine 9
CH - Svizzera 8
RO - Romania 8
IN - India 7
CL - Cile 6
EC - Ecuador 6
TR - Turchia 6
BD - Bangladesh 4
CO - Colombia 4
IQ - Iraq 4
JM - Giamaica 4
UZ - Uzbekistan 4
IR - Iran 3
TZ - Tanzania 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AM - Armenia 2
BO - Bolivia 2
DZ - Algeria 2
EG - Egitto 2
IL - Israele 2
KE - Kenya 2
KG - Kirghizistan 2
SA - Arabia Saudita 2
UG - Uganda 2
VE - Venezuela 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BH - Bahrain 1
BY - Bielorussia 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GR - Grecia 1
LB - Libano 1
MA - Marocco 1
MN - Mongolia 1
MX - Messico 1
NZ - Nuova Zelanda 1
OM - Oman 1
PE - Perù 1
PK - Pakistan 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
SC - Seychelles 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 30.101
Salva come PNG Salva come JPEG
Città #
Woodbridge 6.937
Wilmington 6.847
Houston 5.407
Fairfield 891
Singapore 819
Chandler 551
Ann Arbor 508
Ashburn 408
Seattle 376
Dublin 316
Cambridge 305
Jacksonville 253
Hong Kong 252
Rome 231
Medford 230
Kraków 213
Santa Clara 192
Dearborn 176
Beijing 135
New York 130
Lawrence 108
Council Bluffs 74
San Diego 59
Moscow 53
Zhengzhou 53
Menlo Park 49
Milan 42
Jakarta 41
Mülheim 41
Munich 39
Nuremberg 38
London 32
Creede 30
Helsinki 28
Dundas 24
Falls Church 24
Boardman 21
Dong Ket 20
Phoenix 20
Brussels 18
Colorado Springs 17
Los Angeles 14
Vienna 14
Brno 13
Nanjing 13
Norwalk 13
Seoul 13
Toronto 13
Florence 12
Palo Alto 12
Redwood City 12
University Park 12
Amsterdam 11
Guangzhou 11
San Francisco 11
Cedarhurst 10
Kunming 10
Lappeenranta 10
Mountain View 10
Verona 9
São Paulo 8
The Dalles 8
Manila 7
San Jose 7
Hefei 6
Jiaxing 6
Manitou Springs 6
Ottawa 6
Saint Petersburg 6
Hounslow 5
Jinan 5
Nürnberg 5
Olomouc 5
Parma 5
Shanghai 5
Siena 5
Acton 4
Belo Horizonte 4
Berlin 4
Durban 4
Frankfurt am Main 4
Hangzhou 4
Kilburn 4
New Bedfont 4
North Bergen 4
Palermo 4
Rio de Janeiro 4
San Mateo 4
Tokyo 4
Atlanta 3
Baghdad 3
Buzau 3
Chengdu 3
Civitavecchia 3
Dar es Salaam 3
Detroit 3
Genoa 3
Indiana 3
Johannesburg 3
Madrid 3
Totale 26.411
Salva come PNG Salva come JPEG
Nome #
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 514
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 497
Comet assay and micronucleus test in circulating erythrocytes of Cyprinus carpio specimens exposed in situ to lake waters treated with disinfectants for potabilization 452
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 451
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 450
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice 440
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues 438
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 436
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 435
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 432
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 431
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 430
Population dynamics of HIV-1 subtype B in a cohort of men-having-sex-with-men in Rome, Italy 427
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 427
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 426
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study 420
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 418
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens 407
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment 406
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 398
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test 397
Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon 395
Non-B HIV type 1 subtypes among men who have sex with men in Rome, Italy 394
The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature 392
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens 391
Molecular Epidemiology of HIV Type 1 CRF02_AG in Cameroon and African Patients Living in Italy 387
HIV-1 R5+ /X4- tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029 383
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 380
Dynamics of NRTI resistance mutations during therapy interruption 379
Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria 378
Short communication: Population-based surveillance of HIV-1 drug resistance in cameroonian adults initiating antiretroviral therapy according to the world health organization guidelines 378
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 377
HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design 376
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 376
Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: An observational study using pooled European cohort data 372
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. 371
Temporal change in the use of genotypic resistance testing over the years 1999--2003 371
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia 369
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels 366
Circulation of HIV-1 CRF02_AG among MSM population in central Italy: a molecular epidemiology-based study 362
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 362
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations 361
Clinical relevance of genotypic resistance testing today 357
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project 355
Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir 354
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen 353
Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia 351
Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children 351
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing 350
Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy 348
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score 348
High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians 345
HIV-1 non-B subtypes in Italy: a growing trend 344
Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon 339
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen 339
Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score 336
HIV-1 Genetic Variability and Clinical Implications 332
Characterization of drug resistance mutations in naive and ART-treated patients infected with HIV-1 in Yaounde, Cameroon 330
Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy 323
The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion 318
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 310
Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14 309
Genetic divergence of HIV-1 B subtype in Italy over the years 2003–2016 and impact on CTL escape prevalence 300
The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate + emtricitabine-containing HAART both in vivo and in vitro 296
Impact of pre-therapy viral load on virological response to modern first-line HAART 295
Recent transmission clustering of HIV-1 C and CRF17-BF strains characterized by NNRTI-related mutations among newly diagnosed men in central Italy 279
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 272
Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment 265
Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success 262
Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy 210
New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T) 192
Is the rate of virological failure to cART continuing to decline in recent calendar years? 177
HIV MDR is still a relevant issue despite its dramatic drop over the years 177
Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients 171
Genetic diversity of HIV type 1 in Montenegro 168
Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir 166
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 165
HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: Evidence from routine clinical practice in Cameroon 151
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy 147
Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients 137
Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: Adolescents at high risk of virological failure in the era of "test and treat" 121
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: A multicentre retrospective cohort study 112
Impact of transmitted HIV-1 drug resistance on the efficacy of firstline antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 77
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 70
Impact of analytical treatment interruption on burden and diversification of HIV peripheral reservoir: a pilot study 66
Frequency of atypical mutations in the spike glycoprotein in SARS-CoV-2 circulating from July 2020 to July 2022 in central Italy: a refined analysis by Next Generation Sequencing 65
Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV 65
Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients 65
High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries 61
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice 55
Prevalence and factors associated with HIV-1 multidrug resistance over the past two decades in the Italian Arca database 54
Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease 53
Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings 53
Impact of pre-existent drug resistance on virological efficacy of single tablet regimens in people living with HIV 52
CEDRIC-HIV: la checklist per gli studi sulla resistenza ai farmaci anti-HIV 50
Alarming rates of virological failure and HIV-1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READY-study in Cameroon 50
Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration 48
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses 47
Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile 46
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 46
Totale 28.930
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.563
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.563
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.943 0 0 0 0 0 0 0 646 654 661 459 523
2020/20214.577 489 544 524 624 419 515 599 407 84 121 152 99
2021/20221.345 56 76 83 49 59 91 54 37 346 129 57 308
2022/20231.684 170 137 87 178 159 348 113 168 137 37 102 48
2023/2024683 80 18 29 24 53 126 37 18 19 138 11 130
2024/20252.872 160 906 460 241 141 258 601 105 0 0 0 0
Totale 30.832